Organic Active Ingredients TRIZ Cases

Chitin analogs modulate macrophage activity via TLR4 and TLR2 receptors, reducing serum creatinine and inflammatory cytokines in acute kidney injury.

Formula I compounds inhibit BTK kinase activity with high selectivity over EGFR and ITK, reducing off-target adverse reactions.

Strategic substituent patterns on pyrrolopyridone cores achieve selective BDII inhibition, resolving off-target effects while improving metabolic stability.

Hydroxy-substituted N-Benzylpyrazole derivatives resist HIF activity while preventing body accumulation during repeated once-daily dosing.

Metal borate salts prevent deglycosylation of saponins in aqueous environments, maintaining biological efficacy for animal feed applications.

Helical bend RNA oligonucleotides boost interferon and ISG56 levels by removing complex triphosphate groups.

Genistein and epigallocatechin gallate resolve the contradiction between oxidative protection and active cellular rejuvenation by reducing senescence markers.

Hexahydropyrazine compounds inhibit TLR7, 8, and 9 pathways to treat SLE without the toxicity of broad immunosuppressants.

Therapeutic dsRNA corrects T effector to regulatory cell ratios, reversing immune defects that cause ectopic tissue growth.

Phospholipid conjugates release drugs selectively at diseased sites using PLA2 enzymes, reducing systemic side effects.

Arylsulfonyl pyrazoline carboxamidine derivatives resolve metabolic stability and selectivity trade-offs in 5-HT6 receptor antagonists.

A pharmaceutical composition uses a central nervous system homing peptide to associate with therapeutic agents for targeted delivery.

A nitric oxide hydrogel covalently links polypeptides with protected donors to enable sustained gas delivery.

Propellant-free epinephrine sprays resolve the contradiction between rapid onset and storage stability.

Furo[2,3-d]pyridazinoyl tetrazole derivatives overcome insufficient inhibitor potency and metabolic stability to deliver enhanced bioavailability.

Segmented naloxone auto-injectors deliver stable formulations for immediate opioid reversal without complex preparation.

A pharmaceutical formulation provides selective blockade of voltage-gated sodium channels using a specific sulfonamide compound.

Controlled pH and temperature during crystallization resolve purity complexity trade-offs, yielding diastereoisomerically pure levofolinic acid.

Nitroimidazole-conjugated polymers reduce to amino groups in hypoxic tumors, triggering hydrophilic transitions that enable selective drug release.

Tricyclic compounds target Kras G12D mutations, inhibiting sustained Ras activation and slowing tumor growth.

Administering a COLGALT2 inhibitor prevents harmful galactosylation, delaying degenerative joint damage and reducing osteoarthritis progression.

Segmented bifunctional compounds recruit ubiquitin ligase to degrade ITK, expanding treatment options for inflammatory diseases.

Growth factor gradients attract transfected exosomes to diseased tissue, triggering local protein synthesis and improving delivery precision.

Replacing Lawesson's reagent with phosphorus pentasulfide reduces 1,6-isomer by-products and simplifies purification.

Composite mucoadhesive polymer delivers controlled corticosteroid release to accelerate wound healing while reducing inflammation.

Formulation with specific excipients improves brain penetration despite low solubility.

Antibodies detect FGFR-TACC fusion proteins, resolving diagnostic precision gaps for glioblastoma treatment.

Segmenting cineole into microcapsules inside a gastric-resistant shell reduces gastrointestinal side effects while maintaining therapeutic effectiveness.

Optimized GSK3 inhibitors increase beta-catenin levels and improve motor skills in mice, addressing sub-optimal potency and brain exposure of prior therapies.

Bicyclic peptide ligands bind membrane type 1 metalloprotease with high affinity using a triazinane scaffold to inhibit tumor growth.

Esterifying nucleoside analogs creates prodrugs that resolve the contradiction between high antiviral activity and poor oral bioavailability.

Pre-puberty estradiol benzoate administration prevents boar taint and aggression while eliminating animal pain associated with surgical castration.

Co-solvents solubilize natural progesterone for transdermal patches, resolving insolubility constraints while maintaining patient compliance.

Dynamic PF-07104091 dosing balances antitumor efficacy with safety by adjusting doses based on patient response.

A hydrous adhesive patch uses water-soluble polymer to deliver dexmedetomidine through the skin.

Segmentation and parameter changes generate diverse inhibitor structures that overcome drug resistance while maintaining antitumor efficacy.

Formula I compounds inhibit ALPK1 kinase activity, reducing excessive proinflammatory signaling in Kawasaki disease treatment.

An electro-mechanical infusion pump delivers mTOR inhibitors directly into the cerebrospinal fluid for targeted central nervous system therapy.

Conformationally constrained alpha-helix mimetic compounds modulate cell signaling pathways to inhibit cancer growth.

Nucleotide analogs inhibit hepatitis C virus replication while maintaining metabolic stability and avoiding significant mitochondrial function inhibition.

Triazole agonists resolve stability limits of existing small molecules by enhancing efficacy and extending plasma half-life for heart failure treatment.

Carrier particles shield immunostimulatory oligodeoxynucleotides from nuclease degradation, maintaining stability and enhancing anti-tumor immune responses.

Bio-remodable implants maintain space in bone defects and provide structural support, eliminating the need for surgical removal that disrupts tissue.

Nasal aerosol RNAi agents target Hom-1 mRNA to treat ARDS and autoimmune diseases by reducing inflammatory cytokines.

Substituted BOBA compounds downregulate inflammatory mediators while promoting axonal outgrowth, resolving synapse misconnections in nerve repair.

Segmented thiocolchicoside and analgesic formulations prevent chemico-physical incompatibility while maintaining stable plasma concentrations to reduce side effects.

Novel substituted pyrazolo[4,3-d]pyrimidine compounds inhibit Syk, LRRK2, and MYLK kinases through tailored molecular recognition.

Analyzing specific urine metabolites resolves the trade-off between invasive colonoscopy compliance and low-sensitivity fecal tests.

Polymer backbone RNA targeting compounds use pendant ligands to bind specific RNA motifs, enabling targeted therapeutic interventions for myotonic dystrophy.

An aptamer-siRNA chimera targets BAFF-R on B cells to silence oncogenes, reducing side effects from non-specific chemotherapy.

Alkylamido compounds modulate PPAR and EGF receptors to treat cancer and inflammatory diseases.

Phosphorothioate-linked LNA/DNA mixmers reduce seizure occurrence and provide neuroprotection by targeting underlying pathophysiology.

Formula I derivatives selectively block 11β-HSD1 activity, lowering blood glucose and reducing obesity without unacceptable side effects.

Formula I compounds inhibit PRMT5 enzyme activity, resolving the contradiction between therapeutic efficacy and off-target effects.

Bitopic ligands merge orthosteric and allosteric pharmacophores to resolve the selectivity versus affinity trade-off in GPCR drug design.

Epoxy-phenol resin coating buffers pH between 2.5 and 5, preventing corticosteroid degradation without external agents.

Formula I lipids protect heart tissue from chemotherapy-induced toxicity while maintaining cancer treatment efficacy.

Novel triazolopyridine compounds inhibit phosphodiesterase 10A to modulate cyclic nucleotide signaling pathways in the central nervous system.

Formula I compounds selectively target Rac proteins to inhibit cancer cell proliferation while sparing normal cells from toxicity.

Cleavable linkages release active compounds in vivo, resolving the contradiction between therapeutic activity and water solubility while reducing toxicity.

Imidazopiperazine compounds inhibit CBP and P300 activity, addressing the lack of specific inhibitors for treating proliferative diseases.

HDAC11 and SUV39H2 inhibitors restore chromatin accessibility by increasing H3K27ac levels, addressing ineffective dry AMD treatments.

Selective PDE1 inhibitors reverse cardiac hypertrophy by enhancing cGMP/PKG pathways, addressing inadequate cardiovascular treatments.

Phosphate-buffered saline treatment reduces implant engraftment time from three months to 15 days.

Small molecule PAK1 inhibitors target kinase activity to reduce malignant cell proliferation.

Combining budesonide with 5-amino-2,3-dihydro-1,4-phthalazinedione creates a synergistic pharmaceutical composition.

Combining a PD-1 antagonist with an ATR inhibitor enhances anti-tumor activity by increasing tumor antigen presentation.

Colored water-soluble granules provide visual identification without delaying disintegration, solving the trade-off between readability and dissolution speed.

Formula I compounds activate sigma-1 receptors to provide analgesia without respiratory depression or dependence.

Triazole compounds block glycolate oxidase, reducing endogenous oxalate production and calcium oxalate deposition in kidney stone disease.

Segmented amphiphilic polymers self-assemble into micelles that resolve drug loading versus stability trade-offs, enhancing percutaneous absorption.

Administering a vitamin K composition with UV absorbers elevates plasma levels beyond dietary limits, reducing osteochondral defects in equine animals.

Benzofurazan compounds inhibit amyloid protein aggregation, addressing the lack of effective therapies for fatal neurodegenerative diseases.

Sodium and potassium thiazolidinedione salts minimize sodium reabsorption side effects while maintaining therapeutic efficacy.

STT compound protects dopamine neurons via DUSP10 interaction, while DUSP10 biomarker detection simplifies diagnosis.

Combining desmopressin with a 5-alpha reductase inhibitor reduces required dosage while maintaining therapeutic efficacy.

siRNA compositions target anillin actin-binding protein to induce cytokinesis failure in malignant hepatocytes while preserving normal liver tissue homeostasis.

Replacing phosphodiester bonds with phosphorodithioate linkages protects nucleic acids from nuclease degradation while maintaining gene expression inhibition.

Biodegradable microbeads control anticancer drug release rates to prevent leakage into blood and reduce side effects in liver cancer treatment.

PDGF-AB and Azacitidine transition mature somatic cells into multilineage-potential cells, reducing reliance on high-dose exogenous therapies.

Formula I compounds inhibit O-GlcNAc hydrolase to reduce tau phosphorylation and aggregation in neurodegenerative disorders.

Specific small molecule chymase inhibitors reduce angiotensin II and TGF-beta release to treat cardiac remodeling in heart failure.

A topical composition combines minoxidil, finasteride, and latanoprost to stimulate hair follicles.

Modified benzodiazepine structure delivers analgesic and anticonvulsant effects while preserving gastric mucosa integrity against ulcerogenic damage.

Integrates antihistamines with L-tryptophan and melatonin to improve restorative sleep while reducing side effects from single-agent treatments.

Local Wnt inhibitor administration suppresses fibrocartilage formation and collagen type I expression, enabling durable hyaline cartilage repair.

Lyophilized selexipag formulation maintains chemical stability by preventing premature hydrolysis through precise pH control.

Combines inositol with alpha-lactalbumin to enhance plasma levels and improve fertility outcomes.

SMCC and colloidal silicon dioxide prevent particle segregation during direct compression, ensuring stable low-dose doxepin formulations.

Hydrotropes increase phenolic compound water solubility without chemical modification, avoiding manufacturing cost increases and biological activity loss.

Merges Bcl-2/Bcl-xL inhibitors with chemotherapy to overcome drug resistance while reducing platelet toxicity and enhancing anti-tumor efficacy.

PDE4 inhibitors reduce uric acid levels via renal transport modulation, avoiding hepatotoxicity linked to xanthine oxidase blockers.

A dimethyl trisulfide solvent system enhances water solubility for subcutaneous delivery.

Xylitol and sorbitol protect diclofenac potassium from oxidative degradation while maintaining high bioavailability.

Tricyclo-DNA antisense oligonucleotides target COL7A1 pre-mRNA to skip mutated exons and restore type VII collagen function.

Structural modifications of 7,8-dihydroxyflavone derivatives improve pharmacokinetic stability and reduce metabolic clearance.

Novel nitrogenous heterocyclic compounds inhibit cell proliferation and induce apoptosis to treat tissue fibrosis.